Additionally, genetic manipulation of benign prostate cell fractions based on Epcam/CD44/CD49f expression, followed by in vivo regeneration may suggest mechanisms of tumorigenesis or benign proliferation (BPH) at different developmental stages. This evidence concerns the gene CD44 and benign prostatic hyperplasia.